Vaxart Inc

NASDAQ:VXRTUnited States

Vaxart, Inc., formerly Aviragen Therapeutics, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options. Its products include vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics in Phase IIb SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in Phase II development for condyloma caused by human papillomavirus Types 6 and 11. It has preclinical RSV non-fusion inhibitor program. It has focused its research and drug development capabilities on discovering and developing small molecule compounds that can prevent or treat infectious diseases.

Contact Information

Headquarters

170 Harbor Way, Suite 300SOUTH SAN FRANCISCO, CA, United States 94080

Phone

650-550-3500

Fax

650-871-8580

Executives

Independent Chairman of the Board

Wouter Latour

President, Chief Executive Officer, Principal Financial Officer, Director

Andrei Floroiu

Senior Vice President, Principal Accounting Officer

Margaret Echerd

Senior Vice President, Chief Scientific Officer

Sean Tucker

Independent Director

Todd Davis